Open AccessThis article is
- freely available
Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
Department of Clinical Laboratory, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China
* Author to whom correspondence should be addressed.
Received: 14 December 2012; in revised form: 17 January 2013 / Accepted: 21 January 2013 / Published: 22 January 2013
Abstract: Influenza A virus (IAV) has caused seasonal influenza epidemics and influenza pandemics, which resulted in serious threat to public health and socioeconomic impacts. Until now, only 5 drugs belong to two categories are used for prophylaxis and treatment of IAV infection. Hemagglutinin (HA), the envelope glycoprotein of IAV, plays a critical role in viral binding, fusion and entry. Therefore, HA is an attractive target for developing anti‑IAV drugs to block the entry step of IAV infection. Here we reviewed the recent progress in the study of conformational changes of HA during viral fusion process and the development of HA-based IAV entry inhibitors, which may provide a new choice for controlling future influenza pandemics.
Keywords: influenza A virus; hemagglutinin; viral entry; antiviral drugs
Citations to this Article
Cite This Article
MDPI and ACS Style
Yang, J.; Li, M.; Shen, X.; Liu, S. Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin. Viruses 2013, 5, 352-373.
Yang J, Li M, Shen X, Liu S. Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin. Viruses. 2013; 5(1):352-373.
Yang, Jie; Li, Minmin; Shen, Xintian; Liu, Shuwen. 2013. "Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin." Viruses 5, no. 1: 352-373.